tradingkey.logo

GSK plc

GSK
49.085USD
+0.125+0.26%
收盤 12/26, 16:00美東報價延遲15分鐘
98.81B總市值
13.85本益比TTM

GSK plc

49.085
+0.125+0.26%

關於 GSK plc 公司

GSK plc is a biopharma company. The Company’s segments include Commercial Operations and Research and Development. Its portfolio and pipeline are focused on developing medicines and vaccines in four core therapeutic areas, which are the areas of human health it focuses on to prevent and treat disease: respiratory, immunology and inflammation; oncology; human immunodeficiency virus (HIV), and infectious diseases. Its specialty medicines prevent and treat diseases, from HIV to respiratory diseases, immune-mediated conditions like lupus, and cancer. Its vaccine portfolio includes over 20 vaccines to protect people from diseases and infections throughout their lives. General medicines include inhaled medicines for asthma and COPD to antibiotics. It develops and commercializes preclinical antibody-drug conjugate for Metastatic castration-resistant prostate cancer. Its portfolio also includes Efimosfermin, a fibroblast growth factor 21 (FGF21) analog therapeutic in clinical development.

GSK plc簡介

公司代碼GSK
公司名稱GSK plc
上市日期May 22, 1972
CEOWaterhouse (Deborah)
員工數量68629
證券類型Depository Receipt
年結日May 22
公司地址980 Great West Road
城市BRENTFORD
上市交易所NASDAQ OMX NASDAQ Basic NYSE
國家United Kingdom
郵編TW8 9GS
電話442080475000
網址https://www.gsk.com/
公司代碼GSK
上市日期May 22, 1972
CEOWaterhouse (Deborah)

GSK plc公司高管

名稱
名稱/職務
職務
持股
持股變動
Dr. Hal V. Barron, M.D.
Dr. Hal V. Barron, M.D.
Non-Executive Director
Non-Executive Director
661.21K
+0.43%
Ms. Shobie Ramakrishnan
Ms. Shobie Ramakrishnan
Chief Digital and Technology Officer
Chief Digital and Technology Officer
484.59K
+0.08%
Mr. Charles A. (Charlie) Bancroft
Mr. Charles A. (Charlie) Bancroft
Senior Independent Non-Executive Director
Senior Independent Non-Executive Director
38.91K
+0.88%
Ms. Elizabeth McKee (Liz) Anderson
Ms. Elizabeth McKee (Liz) Anderson
Independent Non-Executive Director
Independent Non-Executive Director
3.00K
+0.87%
Dr. Jeannie Lee
Dr. Jeannie Lee
Independent Non-Executive Director and Scientific & Medical Expert
Independent Non-Executive Director and Scientific & Medical Expert
1.58K
+0.83%
Dr. Harry C. (Hal) Dietz
Dr. Harry C. (Hal) Dietz
Independent Non-Executive Director, Scientific and Medical Expert
Independent Non-Executive Director, Scientific and Medical Expert
--
--
Mr. James Ford
Mr. James Ford
Senior Vice President, Group General Counsel, Legal and Compliance
Senior Vice President, Group General Counsel, Legal and Compliance
--
--
Ms. Sally Jackson
Ms. Sally Jackson
Senior Vice President - Global Communications and CEO Office
Senior Vice President - Global Communications and CEO Office
--
--
Dr. Tony Wood, Ph.D.
Dr. Tony Wood, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Ms. Julie Brown
Ms. Julie Brown
Chief Financial Officer, Executive Director
Chief Financial Officer, Executive Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Hal V. Barron, M.D.
Dr. Hal V. Barron, M.D.
Non-Executive Director
Non-Executive Director
661.21K
+0.43%
Ms. Shobie Ramakrishnan
Ms. Shobie Ramakrishnan
Chief Digital and Technology Officer
Chief Digital and Technology Officer
484.59K
+0.08%
Mr. Charles A. (Charlie) Bancroft
Mr. Charles A. (Charlie) Bancroft
Senior Independent Non-Executive Director
Senior Independent Non-Executive Director
38.91K
+0.88%
Ms. Elizabeth McKee (Liz) Anderson
Ms. Elizabeth McKee (Liz) Anderson
Independent Non-Executive Director
Independent Non-Executive Director
3.00K
+0.87%
Dr. Jeannie Lee
Dr. Jeannie Lee
Independent Non-Executive Director and Scientific & Medical Expert
Independent Non-Executive Director and Scientific & Medical Expert
1.58K
+0.83%
Dr. Harry C. (Hal) Dietz
Dr. Harry C. (Hal) Dietz
Independent Non-Executive Director, Scientific and Medical Expert
Independent Non-Executive Director, Scientific and Medical Expert
--
--

收入明細

單位: USD更新時間: 10月6日 週一
單位: USD更新時間: 10月6日 週一
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
由於公司未披露,未能獲取相關數據
地區USD
名稱
營收
佔比
US
5.49B
51.53%
Rest of world
2.71B
25.44%
Europe
2.45B
23.03%
業務
地區
由於公司未披露,未能獲取相關數據

股東統計

更新時間: 11月15日 週六
更新時間: 11月15日 週六
持股股東
股東類型
持股股東
持股股東
佔比
Dodge & Cox
3.85%
Fidelity Management & Research Company LLC
2.74%
Fisher Investments
1.58%
PRIMECAP Management Company
1.26%
JTC Employer Solutions Trusteee Ltd
0.72%
其他
89.85%
持股股東
持股股東
佔比
Dodge & Cox
3.85%
Fidelity Management & Research Company LLC
2.74%
Fisher Investments
1.58%
PRIMECAP Management Company
1.26%
JTC Employer Solutions Trusteee Ltd
0.72%
其他
89.85%
股東類型
持股股東
佔比
Investment Advisor
9.60%
Investment Advisor/Hedge Fund
7.49%
Research Firm
1.05%
Hedge Fund
0.80%
Bank and Trust
0.10%
Individual Investor
0.06%
Pension Fund
0.06%
Family Office
0.03%
Family Office
0.02%
其他
80.79%

機構持股

更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
1474
388.63M
19.14%
-11.70M
2025Q2
1478
378.08M
18.54%
+5.70M
2025Q1
1494
378.46M
18.50%
+5.08M
2024Q4
1481
355.06M
17.14%
+27.38M
2024Q3
1472
319.97M
15.44%
-30.07M
2024Q2
1585
322.06M
15.54%
-29.11M
2024Q1
1617
318.91M
15.39%
-23.52M
2023Q4
1614
299.81M
14.57%
-35.71M
2023Q3
1570
293.92M
14.35%
-37.46M
2023Q2
1545
286.58M
13.99%
-41.88M
查看更多

股東持股明細

名稱
持股數
佔比
持股變動
變動比例
公告日期
Dodge & Cox
78.76M
3.87%
+106.04K
+0.13%
Jun 30, 2025
Fidelity Management & Research Company LLC
51.48M
2.53%
+872.19K
+1.72%
Jun 30, 2025
Fisher Investments
31.34M
1.54%
+1.31M
+4.35%
Jun 30, 2025
PRIMECAP Management Company
27.73M
1.36%
+2.02M
+7.85%
Jun 30, 2025
JTC Employer Solutions Trusteee Ltd
15.00M
0.74%
-262.98K
-1.72%
Jun 30, 2025
Fidelity Institutional Asset Management
9.53M
0.47%
+10.84K
+0.11%
Jun 30, 2025
T. Rowe Price International Ltd
8.05M
0.4%
+324.11K
+4.20%
Jun 30, 2025
RBC Capital Markets Wealth Management
6.99M
0.34%
+740.61K
+11.84%
Jun 30, 2025
Holocene Advisors, LP
5.61M
0.28%
+304.49K
+5.74%
Jun 30, 2025
State Street Investment Management (US)
6.71M
0.33%
-258.77K
-3.71%
Jun 30, 2025
查看更多

持股ETF

更新時間: 12月6日 週六
更新時間: 12月6日 週六
機構名稱
佔比
VanEck Pharmaceutical ETF
10.83%
The Opal International Dividend Income ETF
4.41%
Sound Equity Dividend Income ETF
3.97%
Keating Active ETF
3.88%
USCF Dividend Income Fund
3.83%
Brandes International ETF
2.87%
Altrius Global Dividend ETF
2.58%
Fidelity Blue Chip Value ETF
1.6%
Lattice Hartford Mltfctr Dev Mkts (ex-US) Str ETF
1.17%
Avantis International Large Cap Value ETF
1.02%
查看更多
VanEck Pharmaceutical ETF
佔比10.83%
The Opal International Dividend Income ETF
佔比4.41%
Sound Equity Dividend Income ETF
佔比3.97%
Keating Active ETF
佔比3.88%
USCF Dividend Income Fund
佔比3.83%
Brandes International ETF
佔比2.87%
Altrius Global Dividend ETF
佔比2.58%
Fidelity Blue Chip Value ETF
佔比1.6%
Lattice Hartford Mltfctr Dev Mkts (ex-US) Str ETF
佔比1.17%
Avantis International Large Cap Value ETF
佔比1.02%

分紅派息

近5年累計派現 20.79B 美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
Feb 05, 2025
GSK.NB Interim Cash Dividend of gross USD 0.434774 paid on Jul 10, 2025 going ex on May 16, 2025
May 16, 2025
Jul 10, 2025
May 16, 2025
Feb 05, 2025
GSK.NB Interim Cash Dividend of gross USD 0.42996 paid on Oct 09, 2025 going ex on Aug 15, 2025
Aug 15, 2025
Oct 09, 2025
Aug 15, 2025
Feb 05, 2025
GSK.NB Approximate final Cash Dividend of gross USD 0.417088 paid on Jan 08, 2026 going ex on Nov 14, 2025
Nov 14, 2025
Jan 08, 2026
Nov 14, 2025
Feb 05, 2025
GSK.NB Interim Cash Dividend of gross USD 0.407568 paid on Apr 10, 2025 going ex on Feb 21, 2025
Feb 21, 2025
Apr 10, 2025
Feb 21, 2025
Oct 30, 2024
GSK.NB Final Cash Dividend of gross USD 0.376892 paid on Jan 09, 2025 going ex on Nov 15, 2024
Nov 15, 2024
Jan 09, 2025
Nov 15, 2024
Jul 31, 2024
GSK.NB Interim Cash Dividend of gross USD 0.392813 paid on Oct 10, 2024 going ex on Aug 16, 2024
Aug 16, 2024
Oct 10, 2024
Aug 16, 2024
May 01, 2024
GSK.NB Interim Cash Dividend of gross USD 0.384301 paid on Jul 11, 2024 going ex on May 16, 2024
May 17, 2024
Jul 11, 2024
May 16, 2024
Feb 01, 2024
GSK.NB Interim Cash Dividend of gross USD 0.404885 paid on Apr 11, 2024 going ex on Feb 22, 2024
Feb 23, 2024
Apr 11, 2024
Feb 22, 2024
Nov 01, 2023
GSK.NB Interim Cash Dividend of gross USD 0.356356 paid on Jan 11, 2024 going ex on Nov 16, 2023
Nov 17, 2023
Jan 11, 2024
Nov 16, 2023
Jul 26, 2023
GSK.NB Interim Cash Dividend of gross USD 0.343532 paid on Oct 12, 2023 going ex on Aug 17, 2023
Aug 18, 2023
Oct 12, 2023
Aug 17, 2023
查看更多

拆合股

公告日期
類型
比率
Jun 24, 2022
Merger
5→4
Jun 24, 2022
Merger
5→4
Jun 24, 2022
Merger
5→4
Jun 24, 2022
Merger
5→4
公告日期
類型
比率
Jun 24, 2022
Merger
5→4
Jun 24, 2022
Merger
5→4
Jun 24, 2022
Merger
5→4
Jun 24, 2022
Merger
5→4

常見問題

GSK plc的前五大股東是誰?

GSK plc的前五大股東如下:
Dodge & Cox
持有股份:78.76M
佔總股份比例:3.87%。
Fidelity Management & Research Company LLC
持有股份:51.48M
佔總股份比例:2.53%。
Fisher Investments
持有股份:31.34M
佔總股份比例:1.54%。
PRIMECAP Management Company
持有股份:27.73M
佔總股份比例:1.36%。
JTC Employer Solutions Trusteee Ltd
持有股份:15.00M
佔總股份比例:0.74%。

GSK plc的前三大股東類型是什麼?

GSK plc 的前三大股東類型分別是:
Dodge & Cox
Fidelity Management & Research Company LLC
Fisher Investments

有多少機構持有GSK plc(GSK)的股份?

截至2025Q3,共有1474家機構持有GSK plc的股份,合計持有的股份價值約為388.63M,占公司總股份的19.14% 。與2025Q2相比,機構持股有所增加,增幅為0.60%。

哪個業務部門對GSK plc的收入貢獻最大?

在FY2025Q2,--業務部門對GSK plc的收入貢獻最大,創收--,占總收入的--% 。
KeyAI